In last trading session, Sutro Biopharma Inc (NASDAQ:STRO) saw 0.52 million shares changing hands with its beta currently measuring 1.21. Company’s recent per share price level of $4.38 trading at $0.22 or 5.29% at ring of the bell on the day assigns it a market valuation of $359.00M. That closing price of STRO’s stock is at a discount of -39.95% from its 52-week high price of $6.13 and is indicating a premium of 54.11% from its 52-week low price of $2.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.66 million shares which gives us an average trading volume of 602.10K if we extend that period to 3-months.

For Sutro Biopharma Inc (STRO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.18. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.73 in the current quarter.

Sutro Biopharma Inc (NASDAQ:STRO) trade information

Upright in the green during last session for gaining 5.29%, in the last five days STRO remained trading in the green while hitting it’s week-highest on Friday, 11/08/24 when the stock touched $4.38 price level, adding 1.79% to its value on the day. Sutro Biopharma Inc’s shares saw a change of 2.10% in year-to-date performance and have moved 23.38% in past 5-day. Sutro Biopharma Inc (NASDAQ:STRO) showed a performance of 32.33% in past 30-days. Number of shares sold short was 2.86 million shares which calculate 4.38 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 11 to the stock, which implies a rise of 60.18% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would drop -82.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -82.65% for stock’s current value.

Sutro Biopharma Inc (STRO) estimates and forecasts

Statistics highlight that Sutro Biopharma Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 5.54% of value to its shares in past 6 months, showing an annual growth rate of -54.97% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -57.00% from the last financial year’s standing.

11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.25M for the same. And 11 analysts are in estimates of company making revenue of 16.08M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.96% during past 5 years.

Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders

Insiders are in possession of 0.96% of company’s total shares while institution are holding 75.28 percent of that, with stock having share float percentage of 76.01%. Investors also watch the number of corporate investors in a company very closely, which is 75.28% institutions for Sutro Biopharma Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at STRO for having 6.91 million shares of worth $20.25 million. And as of 2024-06-30, it was holding 11.2447 of the company’s outstanding shares.

The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 7.71 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.4906 of outstanding shares, having a total worth of $22.59 million.